|Budget Amount *help
¥199,810,000 (Direct Cost: ¥153,700,000、Indirect Cost: ¥46,110,000)
Fiscal Year 2013: ¥41,080,000 (Direct Cost: ¥31,600,000、Indirect Cost: ¥9,480,000)
Fiscal Year 2012: ¥41,080,000 (Direct Cost: ¥31,600,000、Indirect Cost: ¥9,480,000)
Fiscal Year 2011: ¥41,080,000 (Direct Cost: ¥31,600,000、Indirect Cost: ¥9,480,000)
Fiscal Year 2010: ¥41,600,000 (Direct Cost: ¥32,000,000、Indirect Cost: ¥9,600,000)
Fiscal Year 2009: ¥34,970,000 (Direct Cost: ¥26,900,000、Indirect Cost: ¥8,070,000)
Spliceostatin A (SSA) is a chemically stable derivative of anticancer natural product FR901464, which we identified as the first splicing inhibitor that binds the splicing factor SF3b. SSA provides a unique opportunity to analyze novel function of splicing factors and introns. This project aims to elucidate unknown roles of splicing factors by analyzing the mechanisms by which SSA induces a variety of phenotypes. In consequence, we demonstrated that splicing factors targeted by SSA are involved in the regulation of pre-mRNA nuclear retention, transcriptional elongation, polyadenylation, and subcellular localization of nuclear non-coding RNAs.